I’m an analytical chemist by training with a decade of experience in pharmaceutical development, specializing in the quality and regulatory strategy of drug substances and products. Most recently, I served as Associate Director of Analytical Development at QED Therapeutics, a BridgeBio company, where I led outsourced testing and contributed to regulatory filings for a rare disease therapy with commercial approval.
Though I’ve built my career at the bench, my passion lies in biotech strategy — particularly in helping decide which therapies to pursue and how to best communicate their value. BridgeBio’s model of developing a diversified portfolio of rare disease drugs showed me what’s possible when science meets strategic investment. I want to be part of the team that ensures promising treatments don’t get left behind because they’re deemed commercially “unviable.”
To expand my business skillset, I earned my MBA from Duke’s Fuqua School of Business, where I graduated as a Fuqua Scholar and am in the process of earning a Health Sector Management Certificate. I embraced every opportunity for growth — from strategy coursework to hands-on consulting through the Fuqua Client Consulting Practicum (FCCP) — while balancing a full-time career and raising two young sons, Holden and Graham.
Outside of work and school, I’m a former rugby player turned high school coach, a lifelong Tar Heel (B.A. in chemistry from UNC-Chapel Hill), and a dedicated volunteer advocate for survivors of sexual assault. If I’m not chasing after my sons, I’m chasing my two ultimate physical goals: completing a full Ironman and hiking the Appalachian Trail.
I’m not done growing, and I’m not done giving back. I believe the biotech industry needs more voices who understand both molecules and markets — and I intend to be one of them.
